[go: up one dir, main page]

NO20043237L - Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser - Google Patents

Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser

Info

Publication number
NO20043237L
NO20043237L NO20043237A NO20043237A NO20043237L NO 20043237 L NO20043237 L NO 20043237L NO 20043237 A NO20043237 A NO 20043237A NO 20043237 A NO20043237 A NO 20043237A NO 20043237 L NO20043237 L NO 20043237L
Authority
NO
Norway
Prior art keywords
dihydrobenzodiazepine
derivatives
treatment
neurological disorders
neurological
Prior art date
Application number
NO20043237A
Other languages
English (en)
Other versions
NO327697B1 (no
Inventor
Thomas Johannes Woltering
Erwin Goetschi
Geo Adam
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20043237L publication Critical patent/NO20043237L/no
Publication of NO327697B1 publication Critical patent/NO327697B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
NO20043237A 2002-02-06 2004-08-02 Dihydrobenzodiazepin-2-onderivater, farmasoytisk medikament omfattende slike, fremgangsmate for fremstilling av slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom NO327697B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002012 2002-02-06
PCT/EP2003/000859 WO2003066623A1 (en) 2002-02-06 2003-01-28 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
NO20043237L true NO20043237L (no) 2004-08-02
NO327697B1 NO327697B1 (no) 2009-09-14

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043237A NO327697B1 (no) 2002-02-06 2004-08-02 Dihydrobenzodiazepin-2-onderivater, farmasoytisk medikament omfattende slike, fremgangsmate for fremstilling av slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom

Country Status (30)

Country Link
US (1) US6949542B2 (no)
EP (1) EP1474416B1 (no)
JP (1) JP4077411B2 (no)
KR (1) KR20040081486A (no)
CN (1) CN100497333C (no)
AR (1) AR038481A1 (no)
AT (1) ATE374196T1 (no)
AU (1) AU2003205695B8 (no)
BR (1) BR0307474A (no)
CA (1) CA2474219C (no)
DE (1) DE60316538T2 (no)
DK (1) DK1474416T3 (no)
ES (1) ES2294264T3 (no)
GT (1) GT200300028A (no)
HR (1) HRP20040678A2 (no)
IL (1) IL163102A (no)
MX (1) MXPA04007516A (no)
MY (1) MY176608A (no)
NO (1) NO327697B1 (no)
NZ (1) NZ534122A (no)
PA (1) PA8565901A1 (no)
PE (1) PE20031011A1 (no)
PL (1) PL372425A1 (no)
PT (1) PT1474416E (no)
RU (1) RU2315764C2 (no)
SI (1) SI1474416T1 (no)
TW (1) TWI326599B (no)
UY (1) UY27654A1 (no)
WO (1) WO2003066623A1 (no)
ZA (1) ZA200406032B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357433A1 (en) * 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
ATE374030T1 (de) * 2003-07-25 2007-10-15 Hoffmann La Roche Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
CA2623721C (en) 2005-09-27 2014-05-13 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP2010524879A (ja) * 2007-04-19 2010-07-22 エフ.ホフマン−ラ ロシュ アーゲー ジヒドロ−ベンゾ[b][1,4]ジアゼピン−2−オンスルホンアミド誘導体
JP5204232B2 (ja) 2007-08-27 2013-06-05 エフ.ホフマン−ラ ロシュ アーゲー Fxrアゴニストとして使用されるベンゾイミダゾール誘導体
CN101848893B (zh) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
RU2523448C2 (ru) 2008-08-04 2014-07-20 СиЭйчДиАй ФАУНДЕЙШН, Инк, Ингибиторы кинуренин-3-монооксигеназы
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
EP2430022B1 (en) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ, インコーポレイテッド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
JP5649577B2 (ja) 2009-08-21 2015-01-07 大塚製薬株式会社 ベンゾ[b][1,4]ジアゼピン−2,4−ジオン化合物の製造方法
AU2011207229B2 (en) 2010-01-25 2015-02-12 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JP6240063B2 (ja) * 2011-04-28 2017-11-29 ザ ブロード インスティテュート, インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
CA2844521A1 (en) 2011-08-30 2013-03-07 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
DK2750677T3 (en) 2011-08-30 2017-07-10 Chdi Foundation Inc KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND PROCEDURES FOR USE THEREOF
CA2880117C (en) 2012-07-27 2021-04-06 The Broad Institute, Inc. Inhibitors of histone deacetylase
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 mglu2/3 길항제
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
CA2950952C (en) 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CR20170061A (es) 2014-07-17 2017-07-17 Chdi Foundation Inc Métodos y composiciones para el tratamiento de trastornos relacionados con vih
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ[1,5−d][1,4]オキサゼピン化合物(TETRAHYDROIMIDAZO[1,5−d][1,4]OXAZEPINECOMPOUND)
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389189B1 (en) * 1989-03-23 1994-05-18 Pfizer Limited Diazepine antiallergy agents
HRP20020259A2 (en) 1999-10-15 2004-04-30 Hoffmann La Roche Benzodiazepine derivatives
PL357433A1 (en) 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
AU2003205695A1 (en) 2003-09-02
TWI326599B (en) 2010-07-01
KR20040081486A (ko) 2004-09-21
NZ534122A (en) 2006-12-22
CN100497333C (zh) 2009-06-10
SI1474416T1 (sl) 2008-02-29
JP4077411B2 (ja) 2008-04-16
PE20031011A1 (es) 2003-11-29
PA8565901A1 (es) 2003-09-05
PL372425A1 (en) 2005-07-25
US20030166639A1 (en) 2003-09-04
WO2003066623A1 (en) 2003-08-14
GT200300028A (es) 2004-06-11
AU2003205695B8 (en) 2008-05-01
DE60316538T2 (de) 2008-08-21
US6949542B2 (en) 2005-09-27
CA2474219C (en) 2010-04-13
TW200302730A (en) 2003-08-16
RU2315764C2 (ru) 2008-01-27
BR0307474A (pt) 2004-11-09
ATE374196T1 (de) 2007-10-15
CN1633430A (zh) 2005-06-29
DE60316538D1 (de) 2007-11-08
AR038481A1 (es) 2005-01-19
MY176608A (en) 2020-08-18
UY27654A1 (es) 2003-08-29
CA2474219A1 (en) 2003-08-14
PT1474416E (pt) 2007-12-27
ZA200406032B (en) 2005-10-12
AU2003205695B2 (en) 2008-04-03
JP2005522440A (ja) 2005-07-28
EP1474416B1 (en) 2007-09-26
DK1474416T3 (da) 2008-01-14
RU2004126945A (ru) 2005-06-27
HK1078858A1 (zh) 2006-03-24
NO327697B1 (no) 2009-09-14
IL163102A (en) 2011-07-31
MXPA04007516A (es) 2004-11-10
HRP20040678A2 (en) 2005-10-31
ES2294264T3 (es) 2008-04-01
EP1474416A1 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
IS7941A (is) Bensasepínafleiður til að meðhöndla taugasjúkdóma
NO20040097L (no) Kombinasjoner for behandling av inflammatoriske forstyrrelser
NO20052223D0 (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
NO20053678D0 (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ITMI20031311A0 (it) Formulazioni per il trattamento di disturbi artrosici
NO20033803D0 (no) Karbamat for behandling av bevegelseslidelser
NO20033417L (no) Anvendelse av CD23-antagonister for behandling av neoplastiske forstyrrelser
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
NO20033804D0 (no) Karbamatforbindelser for behandling av smerte
NO20030717D0 (no) Forbindelser for behandling av avhengighetsforstyrrelser
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees